Dr. Steven Victor and ReGen Medical Will Be Returning to Dubai Sept. 20-29 at Valiant Clinic

Dr. Steven Victor and ReGen Medical Will Be Returning to Dubai Sept. 20-29 at Valiant Clinic

Dr. Steven Victor and ReGen Medical will be doing Stem Cell Consultations and Treatments at the Valiant Clinic City Walk Dubai UAE

PR Newswire

NEW YORK, Aug. 19, 2019 /PRNewswire/ — Dr. Steven Victor and ReGen Medical are returning to the Valiant Clinic City Walk Dubai to do stem cell consultations and stem cell treatment from Friday, Sept. 20 to Sunday, Sept. 29. 

Stromal vascular fraction cellular (SVFC) therapy, better known as stem cell therapy, is a rapidly expanding set of innovative medical technologies that restore cellular function by enabling the body to repair, replace and regenerate damaged, aging or diseased cells, tissues and organs. The minimally invasive, proprietary procedure utilizes a patient’s own stromal vascular fraction cells (stem cells) from the blood vessels in adipose or fat tissue to significantly boost success rates for patient outcomes in a wide variety of conditions. In addition, there is a vast population interested in stem cell cosmetic procedures, as well as generalized anti-aging rejuvenation.

ReGen Medical at Valiant is certified for the medical tourism market and will operate under US Federal Drug Administration (FDA) standards. ReGen will boast an international staff of physicians who are board-certified or board-eligible and experienced in administering the leading cellular therapies available to treat a variety of conditions. The staff will be led by board-certified physician and ReGen Medical Founder Dr. Steven Victor, who has treated numerous patients for rejuvenation, anti-aging, and diseases with unmet clinical needs. The technology is licensed from New Direction Biosciences.

Steven Victor MD, Regen Medical said, “We are proud to return to Valiant Clinic and the DHA and with them to offer the only dedicated stem cell and regenerative medicine center in the UAE, all while incorporating the latest advancements in cellular therapies to patients worldwide. Further, our return will affirm Valiant Clinic’s leadership role in these fields and help to attract additional talent to our already exceptionally talented and dedicated team.  This type of therapy is going to change the Anti-Aging world and treats not only the outside appearance of aging but also gives the patient a feeling of rejuvenation.”

For consultations and/or treatment please email dubai@regenmedicalpc.com or WhatsApp +1-917-402-9551


Anna Rhodes
ReGen Medical
WhatsApp +1-917-402-9551

Cision View original content:http://www.prnewswire.com/news-releases/dr-steven-victor-and-regen-medical-will-be-returning-to-dubai-sept-20-29-at-valiant-clinic-300903704.html

SOURCE ReGen Medical

Rosen, A Leading Law Firm, Files First Securities Class Action Lawsuit Against SAExploration Holdings, Inc. – SAEX


Rosen, A Leading Law Firm, Files First Securities Class Action Lawsuit Against SAExploration Holdings, Inc. – SAEX

PR Newswire

NEW YORK, Aug. 19, 2019 /PRNewswire/ – Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of SAExploration Holdings, Inc. (NASDAQ: SAEX) from March 15, 2016 through August 15, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for SAExploration investors under the federal securities laws.

Rosen Law Firm, P.A. Logo

To join the SAExploration class action, go to https://www.rosenlegal.com/cases-register-1657.html  or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.


According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the Company improperly did not classify Alaska Seismic Ventures, LLC (“ASV”) as a variable interest entity; (2) the Company had a controlling financial interest in ASV, which required the Company to consolidate ASV in its financial statements; (3) the Company had deficient internal controls over financial reporting; (4) these practices were likely to lead to an investigation of the Company by the SEC; (5) SAExploration would be forced to delay the filing of its quarterly report for the quarter ended June 30, 2019; and (6) as a result, Defendants’ statements about SAExploration’s business, operations and prospects were materially false  and misleading and/or lacked a reasonable basis at all relevant times.  When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 17, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to https://www.rosenlegal.com/cases-register-1657.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or cases@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has secured hundreds of millions of dollars for investors.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 34th Floor
      New York, NY  10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/rosen-a-leading-law-firm-files-first-securities-class-action-lawsuit-against-saexploration-holdings-inc–saex-300903639.html

SOURCE Rosen Law Firm, P.A.

The global motion sickness drugs market at a CAGR of almost 4% during the forecast period

The global motion sickness drugs market at a CAGR of almost 4% during the forecast period

PR Newswire

NEW YORK, Aug. 19, 2019 /PRNewswire/ —

Global Motion Sickness Drugs Market: About this market

Motion sickness drugs are pharmaceutical agents that are used to treat nausea and vomiting caused due to motion sickness. This motion sickness drugs market analysis considers sales from both anticholinergics and antihistamines. Our analysis also considers the sales of motion sickness drugs in Asia, Europe, North America, and ROW. In 2018, the anticholinergics segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as high demand for hyoscine hydrobromide or scopolamine for the prevention of motion sickness will play a significant role in the anticholinergics segment to maintain its market position. Also, our global motion sickness drugs market report also looks at factors such as availability of over-the-counter (OTC) drugs, availability of drugs in multiple dosage forms and growing tourism worldwide. However, nonpharmacological countermeasures to treat motion sickness, the launch of generics, side effects associated with motion sickness drugs may hamper the growth of the motion sickness drugs industry over the forecast period.

Read the full report: https://www.reportlinker.com/p05800697/?utm_source=PRN

Global Motion Sickness Drugs Market: Overview

Availability of over-the-counter (OTC) drugs

The global motion sickness drugs market is predominantly served by the use of generic drugs that are available both as prescription and OTC drugs. Anticholinergics and antihistamines have been regarded as first-line therapy for suppressing and preventing the symptoms associated with motion sickness. Several antihistamines are available as OTC drugs and can be used by pediatric patients. The availability of these medicines OTC increases their accessibility and affordability and provides patients with the freedom of self-medication for the treatment of symptoms associated with minor illnesses. In addition, the availability of OTC drugs reduces the financial burden associated with medication treatment by eliminating the need for a prescription for the purchase of these drugs. This demand for over-the-counter (OTC) will lead to the expansion of the global motion sickness drugs market at a CAGR of almost 4% during the forecast period.

The advent of nauseogenic information technology

The nauseogenic information technology involves the use of nauseogenic vehicles that help in analyzing an individual’s postural stability and can reveal the underlying neural or sensory-motor processes that help in achieving successful body stability. This technology revealed that motion sickness often occurs for a narrow band of frequencies of the imposed oscillation. The frequency band obtained in patients with motion sickness is similar to that produced by postural sway during the natural stance. Further advances in nauseogenic information technology are anticipated to have a positive impact on market growth.

Competitive Landscape

With the presence of several major players, the global motion sickness drugs market is fragmented. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading motion sickness drugs manufacturers, that include Baxter International Inc., GlaxoSmithKline Plc, Johnson & Johnson Services Inc., Pfizer Inc., and Prestige Consumer Healthcare Inc.

Also, the motion sickness drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

Read the full report: https://www.reportlinker.com/p05800697/?utm_source=PRN

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001


Cision View original content:http://www.prnewswire.com/news-releases/the-global-motion-sickness-drugs-market-at-a-cagr-of-almost-4-during-the-forecast-period-300903634.html

SOURCE Reportlinker